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ABSTRACT

ARTICLE HISTORY

The main focus of the current work was to design, evaluate and clinically compare the efficiency of
novel metronidazole (MTD) loaded solid lipid nanoparticles (SLNs) vaginal emulgel with the marketed
vaginal gel (MetronV) against Bacterial vaginosis (BV). Eight formulations were fabricated using 23 full
factorial design and prepared by stearic acid and tween 80 as solid lipid and surfactant, respectively.
Lipid and surfactant concentrations in addition to sonication amplitude were chosen as the independent variables (X1–X3). Then, the prepared MTD loaded SLNs were evaluated based on the dependent
variables which were particle size, polydispersity index, zeta potential, entrapment efficiency, and
cumulative % drug release for 24 h (Y1–Y5). The in vitro release study exhibited a sustained release of
MTD from the SLNs up to 24 h. The optimal MTD loaded SLNs showed nanosized particles (256 nm)
with EE% (52%), and an acceptable ZP value (29.5 mV). Also, the optimized MTD-SLNs formulation
was incorporated into Carbopol emulgel and investigated clinically for its effect against BV. Clinical
studies recorded significant enhancement in therapeutic response of MTD from optimized SLNs vaginal emulgel formulation regarding the clinical treatment (p < .05) and low recurrence rate (p < .001)
against the marketed product. In conclusion, our findings recommend that the fabricated MTD loaded
SLNs vaginal emulgel have significant therapeutic effect in terms of BV management over commercially obtainable marketed vaginal gel (MetronV).
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Introduction
Bacterial vaginosis (BV) is considered to be a major cause of
vaginal discharge in females of childbearing age (Kenyon
et al., 2013). BV is a clinical disorder recognized by a change
in vaginal flora away from Lactobacillus species; which normally produce the lactic acid and hydrogen peroxide that
maintain the acidic pH; toward various bacterial species,
including different anaerobes such as Peptostreptococcus sp.,
Gardnerella vaginalis, Mycoplasma hominis, Staphylococcus
sp., and the Enterobacteriaceae (Pandey et al., 2020). The
altered microbiome causes the production of volatile amines,
destroying the protective epithelium layer of both vagina
and cervix, leading to a rise in vaginal pH (>4.5) and symptoms that varied from symptomatic to asymptomatic infection (Masoudi et al., 2016). Apart from the discomfort of BV,
the case is accompanied with numerous adverse consequences. Furthermore, the existence of other sexually transmitted
infections, for example, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and herpes simplex virus
infection seems to be related to an increased occurrence of
BV (Esber et al., 2015; Soper, 2020). Moreover, untreated BV
is allied with a considerable increase in the risk of HIV attainment (Soper, 2020). It was also stated that women at the

age of 40 and above were more vulnerable to BV due to the
decrease in estrogen level thus varying the living environment of the Lactobacillus sp. (Pandey et al., 2020). Treatment
of BV is mostly applied with oral and vaginal formulations of
antibiotic drugs such as metronidazole (MTD) or clindamycin
that are generally used (Verwijs et al., 2020).
MTD is a drug of choice for the treatment of BV because
it has a minimal effect against the normal vaginal flora lactobacilli (Masoudi et al., 2016). MTD is a drug from the nitroimidazole class in which anaerobic bacteria and some
parasites; under anaerobic conditions, metabolize it into
nitroso radicals, that break microbial DNA’s helical structure,
so preventing synthesis of bacterial nucleic acid and finally
cause bacterial cell lysis (Verwijs et al., 2020). MTD has been
recognized with low levels of antimicrobial resistance due to
that that lactobacilli are not sensitive to MTD (Verwijs et al.,
2020). Unfortunately, the oral administration of MTD is often
accompanied by some drawbacks such as gastrointestinal
tract and nausea, while rarely associated with headache,
vomiting, anorexia, in addition to the bitter or metallic taste
of MTD when taken orally (Brandt et al., 2008). On the other
hand, using MTD in the vaginal route is of great importance
due to its exclusive, low molecular weight thus providing
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superior permeation across the vaginal epithelial membrane
(Bhowmik et al., 2009). Besides, there are merits in the vaginal route; where the application of drug formulations is done
directly in the vaginal cavity for achieving systemic and local
action since the vaginal membrane has a dense network of
blood vessels for effective drug absorption, large surface
area, local effect, self-insertion, high blood supply, and evading the first-pass effect. The vaginal route is mainly used to
treat vaginal infections, sexually transmitted diseases, or for
contraception and semisolid or solid dosage forms are
favored for this route (Kalita et al., 2017).
Nowadays, the level of attention in vaginal drug delivery
nanocarriers has remarkably grown as they aid in the drug
diffusion through vaginal mucus to attain the underlying tissues, therefore overcome the mucus clearance mechanism
(El-Hammadi & Arias, 2015). In addition, nanoparticles, for
example, liposomes, solid lipid nanoparticles (SLNs), and
nanoemulsions have been established for the delivery of
antibacterial drugs and have a significant role in bacterial
eradication (Bazzaz et al., 2016). Various studies show that
the antibiotics’ encapsulation in lipid-based nanoparticles led
to improved antibacterial activity in comparison to the free
antibiotics due to concentrating the antibacterial agents at
the bacterial biofilm interface and work against colonizing
microorganisms (Bazzaz et al., 2016). SLNs are colloidal drug
delivery systems that have the ability to deliver lipophilic
and hydrophilic drugs over an extended period and can
reduce the drug adverse effects by avoiding the environment
from direct interaction with the drugs (Mosallaei et al., 2013).
SLNs are stable drug carriers upon being used in vivo, in
addition, they have noticeable features over conventional
drug carriers (Mosallaei et al., 2013).
Improvement of vaginal drug delivery was assisted by
mucoadhesive gel formulations. The usage of prolongedrelease mucoadhesive vaginal gel was assumed to give several advantages including extended residence time of the formulation at the absorption site because of bioadhesion to the
vaginal mucosa, prolonged drug release, enhanced bioavailability, and less adverse effects of drug and eventually
enhanced patient compliance (Bhowmik et al., 2009).
Carbopol 934 is commonly used as a mucoadhesive polymer
in gel formulations due to it forms an adhesive bond between
a biological and a synthetic surface (Kalita et al., 2017).
To the best of our knowledge, there is no fabricated formulation of MTD-loaded lipid nanoparticles for the vaginal
management of BV. Therefore, our main aim was to formulate and evaluate SLNs loaded with MTD and incorporate in
an emulgel dosage form to be applied vaginally for the
treatment of BV. Moreover, to clinically investigate the effect
of the developed MTD Loaded SLNs vaginal emulgel in comparison with the commonly used market product for the
treatment of BV.

(10th of Ramadan City, Egypt). Stearic acid was purchased
from El-Nasr Pharmaceutical Chemicals Co. (Cairo, Egypt).
Tween 80 was purchased from Fisher Scientific, U.K. Dialysis
tubing cellulose membrane (molecular weight cut off 12,000
Dalton) was purchased from Sigma-Aldrich (St. Louis, MO,
USA). All other materials were of analytical grade.

Materials and methods

Dependent variables
Particle size (Y1)
Polydispersity index (Y2)
Zeta potential (Y3)
Entrapment efficiency (Y4)
Cumulative % drug release (Y5)

Design of experiments
The 23 full factorial experimental design was constructed in
the current study by the use of Deign-ExpertV version 12
(Stat-Ease, Inc., Minneapolis, MN, USA) statistical tool. It was
implemented to statistically optimize the formulation variables with the purpose of preparing MTD Loaded SLNs, in
order to achieve optimal particle size (PS), polydispersity
index (PDI), zeta potential (ZP), high entrapment efficiency
percent (EE%), and prolonged cumulative % drug release.
Eight different trials were designed; three different independent variables were chosen at two levels according to Table 1:
lipid (Stearic acid) concentration (X1), surfactant (Tween 80)
concentration (X2), and sonication amplitude (X3). On the
other hand, the PS (Y1), PDI (Y2), ZP (Y3), EE% (Y4), and cumulative % drug release (Y5) were selected as dependent variables. Desirability was used for the optimized formula
selection which was subjected for further examinations.
R

Preparation of MTD loaded SLNs
SLNs loaded with MTD were prepared by hot homogenization followed by the ultrasonication method as described
before by Badawi et al. (2018). In addition, blank SLNs (void
without adding drug) were prepared using the same conditions for the reason of comparison. The developed dispersions were collected in glass screw-capped tubes and kept in
the refrigerator for further studies.

Characterization of MTD loaded SLNs
Particle size, PDI, and zeta potential determination
The average PS, PDI, and ZP of the prepared MTD-SLNs were
performed using Malvern zeta sizer (Zetasizer Nano-Zs90,
MPT-Z, UK). Exactly, 1 ml was taken from each formulated
nanodispersion and diluted with deionized water prior to
Table 1. Independent and dependent variables and their levels for 23 full factorial experimental design.
Levels
Independent variables
Lipid concentration (X1, %)
Surfactant concentration (X2, %)
Sonication amplitude (X3, %)

1

þ1

3
3
50

5
5
100
Constraints

Materials
Metronidazole, Carbopol 934 were kindly donated by
Egyptian International Pharmaceutical Industries Co., EIPICO,

Minimize
Minimize
Maximize
Maximize
Maximize
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examinations to confirm that the light scattering intensity is
in the instrument’s sensitivity range (Wang et al., 2012).
Results were the average of three measurements.

Entrapment efficiency percent (EE%) determination
The prepared MTD-SLNs dispersions were centrifuged using
a cooling centrifuge (2-16KL, Sigma Laborzentrifugen GmbH,
Osterode am Harz, Germany) at 12,000 rpm for 2 h at 4  C
(Badawi et al., 2018). The supernatant was collected to measure the free drug concentration using ultraviolet (UV) spectrophotometer (V-630, Jasco, Tokyo, Japan) at 277 nm
(Nohemann et al., 2017). The entrapment efficiency percent
EE% was calculated according to the following equation
(Badawi et al., 2018):
EE% ¼

W initial drug W free drug
 100
W initial drug

‘W initial drug’ is the amount of initial drug used for
the assay
‘W free drug’ is the amount of free drug measured in the
supernatant

Transmission electron microscope (TEM)
Morphology of the prepared MTD-SLNs was detected via
transmission electron microscopy (Model JEM-1230, Jeol,
Tokyo, Japan). One drop of the diluted sample was applied
to a copper grid coated with carbon film after being stained
with phosphotungstic acid (1%; w/v) as a negative stain
(Montenegro et al., 2012).

Formulation of MTD-SLNs vaginal emulgel
The optimized formula of MTD-SLNs was selected for the
preparation of vaginal emulgel. To prepare the emulgel formulations, the emulgel forming polymer (Carbopol 934) was
dispersed in deionized water in a concentration of 1% and
mixed for 10 min. Subsequently, an accurate amount of the
optimized MTD-SLNs dispersion was added and stirred using
a high-speed stirrer at almost 1000 rpm for 30 min then the
addition of Triethanolamine as a pH adjusting agent was
done, to yield emulgel with good consistency containing a
final concentration of 0.75% MTD (Kesharwani et al., 2016).
As well, 0.75% MTD gel formulation (without nanoparticles)
was prepared to be evaluated and compared with the optimized MTD-SLNs emulgel formulation.

Characterization of MTD-SLNs vaginal emulgel
Physical examination, spreadability, and pH
determination
The MTD-SLNs emulgel formula in addition to the MTD gel
formula was inspected visually for their homogeneity color,
syneresis (mean expulsion of a liquid from an emulgel). In
addition, spreadability was examined via placing 0.5 g emulgel inside a pre-marked circle of 1 cm diameter on a glass
plate over which another glass plate was placed. A mass of
500 g was left to rest on the upper glass for 5 min. then the
increase in the diameter was measured (Wang et al., 2012).
In addition, for pH determination, exactly one gram of the
formulated MTD-SLNs emulgel was dispersed in 100 ml of
water. The pH was then measured using a pH meter
(JENWAY 350, UK) (Madan et al., 2014).

Determination of the drug content
In vitro drug release studies
The in vitro release of MTD from all developed formulae of
MTD-SLNs was performed by the dialysis bag technique
€ nu
€llu
€ et al., 2015) in dissolution media consisting of phos(Go
phate buffer solution pH 4.5 (Yang et al., 2019; Albash et al.,
2020). A certain amount of MTD – SLNs dispersion was measured and transferred to the bags which were then immersed
in the dissolution media. The temperature was controlled via
a shaking water bath (WSB-18, Daihan Scientific Co. Ltd.,
Gangwon, South Korea) at 37  C and shaken at 100 rpm. The
precise volume of the samples was withdrawn at regular
time intervals till 24 h and replaced with an equal volume of
fresh dissolution media. The cumulative release of MTD from
lipid nanoparticles was determined spectrophotometrically at
277 nm (Nohemann et al., 2017).

Selection of the optimized formula
The optimized formula was selected after data analysis by
Design ExpertV software. This was done via applying the constraints on all independent variables to obtain particles with
the least PS and PDI as well as high ZP and EE% in addition
to sustained cumulative % drug release. The suggested optimized formula was prepared and characterized.

One gram from MTD-SLNs emulgel or MTD gel was dissolved
in 50 ml of ethanol using a standard volumetric flask.
Following a 1 ml of 50 ml volumetric flask was diluted in a
10 ml volumetric flask. The amount of drug for each one
gram gel was detected spectrophotometrically at 277 nm
(Nohemann et al., 2017) and the drug content was calculated
using the calibration curve (Wang et al., 2012).

Rheological studies
The viscosity of the prepared MTD-SLNs emulgel and the
MTD gel was measured using Brookfield viscometer (DV-II
Pro Viscometer, Boston, MA, USA) with spindle (T-D). The
sample was exposed to continuous speed rate variation
upward from 1 to 100 s1 then backward from 100 to 1 s1
at 25 ± 1.0  C and the examined viscosity was recorded
(Mekkawy et al., 2013).

R

In vitro release studies
The in vitro release of MTD from the prepared emulgel formula in comparison to the MTD gel formula was performed
by the dialysis bag technique. A specific amount of
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MTD-SLNs emulgel formulae was added to the presoaked
dialysis bag. Subsequently, the bag was immersed in the dissolution media; then the experiment was accomplished as
aforementioned (Cassano & Trombino, 2019). The release
profile of MTD was examined by fitting the experimental
data to equations that describe different kinetic orders
namely zero order, first order, and Higuchi diffusion kinetics.
Based on the high regression coefficient value the kinetic
order was selected.

Clinical study of the MTD-SLNs vaginal emulgel
Setting and ethical approval
Patients’ selection was accomplished in the Obstetrics &
Gynecology Department, Faculty of Medicine, Alzahraa
University Hospital. Sixty married females who complained
from BV and aged between 18 and 44 years (reproductive
age) were chosen for the study. Moreover, essential ethical
permission was obtained from the ethical committee office
code number: 202009379 Al-Azhar University, as well as written informed consent, which was essential for participation in
the study. Conduction of the study was done in agreement
with the ethics that have their origin in the Declaration of
Helsinki Good Clinical Practice. The staff notified the participants with the aims, dates, treatments, diet, probable risks,
and general activities during the clinical part of the study.

Patients
The current study included sixty female patients who suffered from one or more of the following: grayish-white vaginal discharge, malodor, itching, dyspareunia, and abdominal
pain, then confirmed to be having BV via diagnosis using
Amsel’s criteria and Gram stain. The exclusion criteria were
pregnancy, lactation or taking antibiotics, immunosuppressive, anti-parasitic, anti-coagulant, or vaginal drugs during
the last 14 days, and using an intrauterine device. Together
with having a history of known medical diseases, abnormal
uterine bleedings, having cervicitis, and cervical intraepithelial neoplasia. Lastly, any women with Trichomonas or
Candida in their samples were excluded from this
study cases.

Study design
The recruited patients were subjected to complete history
taking which includes: a personal history (age, occupation,
and education), menstrual history (last menstrual period),
and obstetric history (parity and contraceptives).
BV was confirmed at baseline during pelvic checkup using
Amsel’s criteria and Gram stain. At least 3 out of 4 Amsel’s
criteria must be fulfilled to make a diagnosis of BV
(Chavoustie et al., 2015). They include:
 Vaginal pH more than 4.5.
 Fishy smell release upon addition of alkali (10% potassium hydroxide).
 Characteristic
thin,
grayish-white
discharge
on
examination.
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 Occurrence of clue cells on microscopy of vaginal fluid
mixed with normal saline.
Accordingly, any signs of vaginitis and abnormal discharges were detected and examined vaginally via a sterile
speculum. The pH of the vaginal secretions was examined by
placing a sample from the lateral wall of the vagina on pH
paper. Samples of vaginal secretion were taken from the
upper-lateral side of the vaginal wall via a sterile swab.
Afterward, the samples were placed onto three different
slides. Normal saline was added to the first followed examination by (X10) and (X40) objective lenses of the microscope
for the presence of squamous epithelial cells with adherent
bacteria ‘clue cells.’ While, a drop of 10% KOH solution was
added to the second specimen to perform the Whiff test
(potassium hydroxide release to the vaginal fluid) and to
assess amine (fishy) odor, and inspected microscopically for
the probable occurrence of Candida (hyphae or mycelia).
Eventually, the third specimen was used for Gram stain and
BV diagnosis. Gram stains were prepared by spreading the
vaginal secretion by a sterilized bacteriological loop on a
clean slide and allowing it to dry in air and fixed by passing
the slide with the smear side uppermost over the flame for
2–3 times to heat-fix smears to the slides. The smear was
covered with crystal violet, the primary stain, for 20 s followed by gentle rinsing off the stain with water. The smear
was covered with Gram’s iodine, the mordant, for 1 min followed by pouring off the excess Gram’s iodine. The acidalcohol decolorizer was run over the smear until the solution
appeared clear followed by gentle rinsing with water. The
smear was covered with diluted basic fuchsin, the counterstain, for 20 s followed by gentle rinsing with water and placing slides at an angle to air dry. The dried smear-slide was
examined by oil immersion (X100) objective lenses of the
microscope for squamous epithelial cells with adherent coccobacilli ‘clue cells’ (Chavoustie et al., 2015; Zare et al., 2019).
This study is a randomized clinical study. Eligible patients
were randomly assigned into two groups each one consisting of 30 women, group (A) and group (B). Group A received
the MTD-SLNs vaginal emulgel (0.75%), while group B
received the marketed product commonly used in the treatment of BV (MetronV), vaginal gel (0.75%). The patients were
required to use the assigned treatment once daily at bedtime for five consecutive days and to avoid vaginal douching/over washing. The women reported for examination on
day 3 and then at the end of treatment on day 5. Also, a follow-up for the patients after 3 months to check for recurrence was performed.
In the follow-up visits, the whole diagnosis procedures
were repeated and the BV treatment were considered effective if no Amsel’s criteria and negative Gram stain results
were noticed. All the data were collected and statistically analyzed.
R

Statistical analysis
For the clinical study part: The statistical analysis was done
using SPSS statistical software (version 20.0). Chi-square was
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used to evaluate the significance of the difference between
quantitative variables in addition p  .05 was considered to
be statistically significant while p  .01 was considered to be
highly significant. The data are displayed as the mean ± standard deviation.

Results and discussion
Factorial design optimization
The obtained results are shown in Table 2. Concerning, the
design analysis results in Table 3, the selected model was
two-factor interaction and it was observed that the predicted
R2 values were in agreement with the adjusted R2 values in
all studied responses (within approximately 0.2 of each
other) except in PDI and ZP. The adequate precision value of
the model usage is for verifying its adequacy to navigate the
design space in which a ratio greater than 4 is considered to
be desirable (Albash et al., 2021) and that was detected in all
responses as presented in Table 3. To demonstrate the effect
of the independent variables and their interactions on the
dependent ones, three-dimensional response surface plots
(Figure 1) and contour plots (Figure 2) were constructed.

Impact of formulation variables on different
studied responses
PS of the fabricated MTD-SLNs was within the nano-range
from 175.5 to 362.9 nm, as displayed in Table 2. ANOVA analysis demonstrates that both X1 and X2 had a significant
impact on the PS of the fabricated MTD-SLNs with p-values
equal to .0385 and .0063, respectively. It was found that
there was a positive relation between lipid concertation (X1)
and PS where increasing the concentration of lipid resulted
in particles with large size. This may be due to the reduced
sonication efficiency at higher lipid contents because of high

sample viscosity, which led to larger particles (Hosny, 2016).
Moreover, deficiency of adequate surfactant to surround the
particle surface is the probable cause for large particle size
(Shah, Eldridge, et al., 2014). Furthermore, high lipid contents
led to high particle concentration that increases the possibil€ller,
ity of particle contact and aggregation (Freitas & Mu
1998). While surfactant concentration (X2) had an inverse
relation with PS where increasing the concentration of surfactant resulted in smaller PS of the prepared MTD-SLNs. This
could be described by the reduced interfacial tension
between lipid and aqueous phases when the concentration
of surfactant increased, thus regulate the aggregation of the
particles and resulting in lower particle size (Mehnert &
M€ader, 2001). Moreover, as previously stated, particle surface
stabilization can occur with higher surfactant concentration
which develops a steric barrier on the lipid matrix surface,
hence preventing aggregation (Harivardhan Reddy &
Murthy, 2005).
Regarding PDI, a low value approaching zero illustrates a
perfectly homogenous dispersion with a narrow PS range.
While, a high value approaching one represents a highly polydisperse dispersion (Albash et al., 2021). All variables
showed no significant effect with p-values of .83, .055, and
.28 for (X1), (X2), and (X3), respectively. The PDI of the measured MTD-SLNs ranged from 0.22 to 0.57 which showed that
the prepared formulations showed good homogeneity (Table
2) (Badawi et al., 2018).
The stability of nanoparticles is commonly indicated by
ZP which is employed to measure the nanoparticles’ charge
(Badawi et al., 2020). ZP of the developed formulations
ranged from 25.0 to 32.1 mV (Table 2). The prepared formulations exhibited negative zeta potential due to the occurrence of terminal carboxylic groups in the lipids (Badawi
et al., 2020). It is worth stating that there was a small difference in ZP values, but the variation was not significant.

Table 2. Composition and results of the 23 full factorial design for formulations of MTD loaded SLNs.
Variables

Responses
Y1
(nm)
230 ± 9.7
225 ± 7.2
311 ± 11.3
209 ± 5.4
231 ± 6.9
301 ± 13.3
362 ± 8.5
175 ± 10.6

Y2

Y3
Y4
Y5
X2
X3
X1
Formulae code
(%)
(%)
(%)
(mV)
(%)
(%)
SLN1
5.00
5.00
50.00
0.24 ± 0.11
25.9 ± 3.6
58.7 ± 4.9
79.5 ± 5.1
SLN2
3.00
3.00
50.00
0.29 ± 0.02
29.0 ± 1.9
48.6 ± 5.7
89.1 ± 4.6
SLN3
3.00
3.00
100.00
0.57 ± 0.13
30.9 ± 4.4
42.5 ± 3.1
81.2 ± 3.9
SLN4
3.00
5.00
100.00
0.28 ± 0.08
28.5 ± 5.1
44.3 ± 5.9
82.7 ± 6.5
SLN5
5.00
5.00
100.00
0.30 ± 0.07
32.1 ± 2.4
52.8 ± 2.1
72.5 ± 2.8
SLN6
5.00
3.00
50.00
0.48 ± 0.19
28.8 ± 5.6
65.6 ± 3.4
81.4 ± 6.1
SLN7
5.00
3.00
100.00
0.40 ± 0.09
30.1 ± 2.3
60.5 ± 7.1
71.7 ± 3.1
SLN8
3.00
5.00
50.00
0.22 ± 0.05
25.0 ± 4.5
48.1 ± 6.8
90.5 ± 5.3
Results are expressed as the mean of 3 replicates ± SD.
SLNs: solid lipid nanoparticles; X1: lipid concentration; X2: surfactant concentration; X3: sonication amplitude; Y1: particle size; Y2: polydispersity
index; Y3: zeta potential; Y4: entrapment efficiency; Y5: cumulative % drug release.

Table 3. Results of regression analysis of the responses.
Response
Y1, Particle size
Y2: Polydispersity index
Y3: Zeta potential
Y4: Entrapment efficiency
Y5: Cumulative % drug release

Adequate precision
10.98
4.14
5.05
10.46
25.37

R2
0.91
0.68
0.73
0.93
0.98

Adjusted R2
0.85
0.45
0.52
0.86
0.97

Predicted R2
0.66
0.25
0.09
0.71
0.94

p-Value
.0126
.163
.127
.012
.0003
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Figure 1. Three-dimensional response surface plots for the impact of the investigated variables on (a) particle size, (b) PDI, (c) zeta potential, (d) entrapment efficiency %, and (e) cumulative drug release %.

EE% refers to the amount of drug, expressed as a percentage, entrapped by the nanoparticles in comparison to the
amount of drug added (Shah, Malherbe, et al., 2014). The
capability of the formulated nanoparticles to accommodate a
sufficient amount of drug is a vital constraint for its possible
application as a drug delivery system. The entrapment efficiency of the prepared MTD-SLNs formulations varied from
42.5% to 65.6% (Table 2). ANOVA results revealed that X1
only had a significant impact on the EE% of the fabricated
MTD-SLNs with p-value equal to .0031. A positive effect with
increasing the lipid concentration (X1) was detected. This
could be due to that higher lipid amount offers additional
space in order to encapsulate an extra amount of drug during SLNs preparation. In addition, it leads to a decrease in
the rate of drug diffusion into the external phase due to
higher lipid phase viscosity and accordingly exhibited higher
entrapment efficiency (Hosny, 2016).
The in vitro release profile of MTD-SLNs formulations over
24 h is displayed in Figure 3 in which a biphasic release pattern was obvious. This behavior has been stated for SLNs
(Nabi-Meibodi et al., 2013). Burst drug release is probably
due to the drug attached to the nanoparticles’ surface,
whereas sustained release is regularly due to the entrapped
drug in the lipid core (Tran et al., 2014). Cumulative MTD
release over 24 h ranged from 71.7% to 90.5% as shown in
Table 2. ANOVA results show that both X1 and X3 had a significant impact on the cumulative MTD release of the fabricated MTD-SLNs with p-values equal to .0002 and .0003,
respectively. X1 had a negative influence on the MTD release
which could be clarified by the reduced surface area due to
large particle size thus, decreasing the release rate
(Mainardes & Evangelista, 2005). Moreover, increasing the

lipid concentration leads to higher viscosity and more rigid
solidified nanoparticles which may also delay the diffusion of
the drug to the dissolution medium (Emami et al., 2015).
Also, X3 had a negative impact on the MTD release as it led
to the formation of large particles and hence small surface
area obtainable for dissolution medium so led to retarded
release (Venkateswarlu & Manjunath, 2004).

Morphology examination
Figure 4 revealed that the transmission electron micrograph
of the MTD-SLNs samples presented spherical particles with
no aggregation. We reported only one image as an example
because all images attained were alike.

Selection of the optimized MTD-SLNs formulation
To select the optimized formula, certain conditions were set
in Design Expert software version 12. These conditions
favored nanoparticles with the highest EE%, cumulative %
drug release, ZP, and lowest PS as well as PDI. The optimized
formula which met these criteria was found to be composed
of stearic acid as a lipid 4%, tween 80 as a surfactant 4%,
and using a sonication amplitude of 75%. The observed
responses of MTD-SLNs optimized formula were EE% of 52%,
cumulative % drug release after 24 h of 87%, a PS of 256 nm,
a PDI of 0.35, and a ZP of 29.5 mV, which are in close
agreement with the predicted values.

MTD-SLNs vaginal emulgel
To maximize the benefit of the MTD-SLNs optimized formula,
it was incorporated into emulgel structure using Carbopol
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Figure 2. Contour plots for the impact of the investigated variables on (a) particle size, (b) PDI, (c) zeta potential, (d) entrapment efficiency %, and (e) cumulative
drug release %.

Figure 3. In vitro release of MTD from the prepared SLNs through cellulose membrane over 24 h. MTD, metronidazole; SLNs, solid lipid nanoparticles.

934 emulgel forming agent in order to enhance the application and vaginal retention of the drug.

Physical examination, spreadability, pH determination,
and drug content
The prepared optimized MTD-SLNs emulgel, as well as the
MTD gel formulae, were white with a smooth and homogenous appearance. One of the important formulation parameters for vaginal compatibility is the pH (Rençber et al., 2017).
The pH values were in the acceptable range, as per the pH

of the vagina (around 3.5–4.5) with the purpose of avoiding
any vaginal irritation upon application, which indicates the
suitability of the formulations for the vaginal application
(Mudhney et al., 2015). Results of the pH are shown in
Table 4.
Spreadability of the formulation is a vital characteristic
when considering patient compliance as it is responsible for
precise dosage delivery to the target site and ease of application on the mucosa (Rençber et al., 2017). Formulations
with high values of spreadability permit easy application and
hence higher surface area obtainable for drug permeation.
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Figure 4. Morphology of MTD-SLNs obtained from batch SLN8. MTD, metronidazole; SLNs, solid lipid nanoparticles.
Table 4. Physical characters of prepared vaginal formulations.
Formula Code
Color
Homogeneity
G1
White
Homogeneous
G2
White
Homogeneous
Results are expressed as the mean of 3 replicates ± SD.
G1: MTD-SLNs emulgel formula; G2: MTD gel formula.

Texture
Smooth
Smooth

pH
4.94 ± 0.12
5.11 ± 0.06

Spreadability (cm)
7.41 ± 0.10
6.52 ± 0.21

Drug Content (%)
99.30 ± 0.58
98.99 ± 0.63

The prepared formulations gave an acceptable range as
shown in Table 4, which indicates good spreadability by a
small amount of shear (Bachhav & Patravale, 2010). In addition, the prepared formulae exhibited an acceptable range
of drug content and low standard deviations (Table 4). It
confirms that the drug is reliably dispersed in the vaginal
formulations.

Rheological properties
The rheological property of the vaginal semisolid formulations affects their potential for vaginal application in a fundamental way because the shear rate on the preparation is
high during vaginal application. If the viscosity is too high,
this will lead to difficulty in application and thus irritation.
On the other hand, if it is too low, it will result in increased
drainage (Mudhney et al., 2015). Therefore, the formulation
should have an optimum viscosity for easy application to the
vaginal mucosa. Commonly, viscosity values in an optimum
range enhance the retention time & mucoadhesive property.
The viscosity values were 90,500 and 50,346 cp at speed
5 rpm for G1 and G2, respectively. All prepared formulae
exhibited non-Newtonian pseudoplastic flow with shear-thinning behavior as well as thixotropy, representing that the
disarranged viscosity of the system decreases with the
increase in shear rate (Yao & Patel, 2001). On the basis of
rheological studies, the prepared formulations showed good
viscosity and spreading on vaginal application and the
results are in agreement with Mudhney et al. (Mudhney
et al., 2015).

Figure 5. In vitro release of optimized MTD-SLNs vaginal emulgel (G1) in comparison to MTD gel (G2) formulations through cellulose membrane over 24 h.
Values are presented as means ± SD.

release rates of G1 and G2 formulations after 2 h were 55%
and 100%, respectively. While the release rate of MTD from
G1 at the end of 24 h reached 82%. This was reinforced by
the fact that the conventional gel formulation of MTD (G2)
exhibited fast release of the drug which is in accordance
with Maru et al (Maru et al., 2012). On the other hand, MTDSLNs emulgel formulation (G1) showed a prolonged release
rate which may be explained by the difference in viscosity of
the formulations where the release amount of the drug
decreases as the viscosity increases (Rençber et al., 2017).
Furthermore, the investigated formulation (G1) demonstrated
release characteristics following Higuchi kinetics. This result
recommended that the primary release mechanism of MTD
from the lipid matrix and the emulgel is diffusion.

In vitro release studies
The release study of MTD from vaginal formulations was performed using the dialysis bag membrane technique (Cassano
& Trombino, 2019). In vitro release profiles of MTD from G1
and G2 in phosphate buffer solution pH 4.5 were displayed
in Figure 5. It was observed from the obtained data that, the

Clinical study of the MTD-SLNs vaginal emulgel
The clinical study was done to evaluate the prepared MTDSLNs vaginal emulgel in comparison with the market product
MetronV (vaginal gel) which is commonly used in the
R
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Table 5. Demographic data of the studied groups.

Variables
Age (years)
BMI (kg/m2)
Occupation
House wife
Worker
Education
Primary
Secondary
Collage
Parity

Group A
n ¼ 30
Mean ± SD

Table 8. Comparison between the studied groups at day 5 of treatment.

Group B
n ¼ 30
Mean ± SD

t

p-Value

40.21 ± 1.12
29.12 ± 1.63

41.23 ± 2.03
28.71 ± 1.45

1
1

.737
.648

20 (66.66%)
10 (33.33%)

19 (63.33%)
11 (36.66%)

1
1

.732
.521

10 (33.33%)
12 (40%)
8 (26.67)
4.23 ± 2.1

9 (30%)
15 (50%)
6 (20%)
3.4 ± 5.2

1
3
2
1

.652
.246
.547
.683

Table 6. Comparison between the studied groups before the start of
the treatment.
Group A
Amsel’s criteria
PH > 4.5
Vaginal discharge
KOH þ ve
(Wife test)
Malodor
Itching
Dyspareunia
Abdominal pain
Gram stain þ ve

Group B

Chi-square

n
30
28
26

%
100%
93.33%
86.67%

n
30
27
28

%
100%
90%
93.33%

t
1
1
1

p-Value
.837
.672
.715

30
26
25
20
30

100%
86.67%
83.33%
66.67%
100%

30
28
24
21
30

100%
93.33%
80%
70%
100%

2
2
1
1
1

.837
.574
.626
.635
.837

Table 7. Comparison between the studied groups at day 3 of treatment.
Group A

Group B

Chi-square

Amsel’s criteria

n

%

n

%

t

PH > 4.5
Vaginal discharge
KOH þ ve
(Wife test)
Malodor
Itching
Dyspareunia
Abdominal pain
Gram stain þ ve

8
5
2

26.67%
16.67%
6.67%

15
11
5

50%
36.67%
16.67%

19
17
2

p-Value
.003
.003
.143

5
4
9
8
4

16.67%
13.33
30%
26.67%
13.33%

10
12
10
10
10

33.33%
40%
33.33%
33.33%
33.33%

16
22
17
19
17

.042
.000
.542
.412
.002

*Significant difference between the results of both groups.

treatment of BV. Sixty female patients were enrolled successfully for 5 days in this study to evaluate the treatment of BV
and the patient’s demographics were recorded as shown in
Table 5. The diagnosis was clinically performed based on
Amsel’s criteria and verified via microbiological examination.
Every 30 patients were randomly enrolled in a group; Group
A received MTD-SLNs vaginal emulgel and Group B received
the market product MetronV vaginal gel. The treatments
were applied once daily at bedtime for 5 days. Firstly, baseline signs, symptoms, and evaluation were taken for each
patient to register the pretreatment information as shown in
Table 6 to be able to assess the clinical efficacy and safety of
the treatment regimen. In addition, the patients in each
group were followed up by clinical and microbiological
examination at day 3 as shown in Table 7, and at the end of
the treatment (day 5) as shown in Table 8. Furthermore, the
patients were followed up for any sign of allergy and after
3 months of treatment to investigate the incidence of recurrence infection (Table 9). The contributors showed good
R

Group A

Chi-square

Group B

Chi-square

Variables

n

%

n

t

p-Value

PH > 4.5
Vaginal discharge
KOH þ ve
(Wife test)
Madodor
Itching
Dyspareunia
Abdominal pain
Gram stain þ ve

3
2
2

10%
6.67%
6.67%

5
5
2

16.67%
16.67%
6.67%

1
2
1

.243
.143
.841

2
1
2
3
2

6.67%
3.33%
6.67%
10%
6.67%

2
1
4
3
4

6.67%
3.33%
13.33%
10%
13.33%

1
1
1
1
1

.832
.826
.625
.782
.427

%

Table 9. Incidence of complication of the treatment in both groups.
Group A

Group B

Chi-square

Variables

n

%

n

%

t

p-Value

Allergy
Recurrence of infection of the
treatment in 3 months

2
2

6.66%
6.66%

4
10

13.33%
33.33%

2
17

.583
.001

*Significant difference between the results of both groups.

acceptance of the formulations and stated no adverse feedbacks while using them or afterwards.
The study results showed no significant (p > .05) difference between the two examined groups in terms of demographic, as age, occupation, level of educations, and parity
(Table 5). There is no significant difference between both
groups before treatment as regards Amsel’s criteria, symptoms and gram stain results (Table 6). After 3 days of treatment, there was a clinical improvement of symptoms of the
patients from both group A and group B. However, the
improvement in group A was much better as there was a
significant decrease in Amsel’s criteria; where the pH did not
change in only 26.67% in group A while 50% in group B and
the vaginal discharge was present in only 16.67% of the
patients receiving MTD-SLNs emulgel in comparison to
36.67% in the group receiving Metron. There was also a significant enhancement in the symptoms of women receiving
MTD-SLNs emulgel in contrast to the group receiving market
product where the cases still complained of malodor 16.67%
to 13.33% and itching still present in 13.33% to 40% respectively in group A to group B respectively (Table 7). On the
other hand, although there was a reduction in the dyspareunia and abdominal pain, it was not significant. As for the
gram stain under an electron microscope at the start of the
study 100% of both groups were positive (n ¼ 30 per group),
upon receiving the treatment for only 3 days most of the
group receiving MTD-SLNs emulgel showed negative results;
only 4 patients remained positive (13.33%), while 10 patients
remained positive (33.33%) in group B, which was statistically
highly significant.
At the end of the treatment day 5, the patients in both
groups showed improvement, yet there was no significant
difference between the groups in regard to Amsel’s criteria,
symptoms, and gram stain (Table 8). The incidence of complications was higher in group B than in group A as the
cases with allergy equals 13.33% in group B and 6.6% in
group A, however, the variation between the studied groups
is not statistically significant (p > .05). Nevertheless, the
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Figure 6. Incidence of complication of the treatment in both groups.

incidence of recurrence of infection within 3 months of treatment was significantly lower (p ¼ .001) in group A (16.66%)
compared to 33.33% of group B (Table 9 and Figure 6).
Pertaining to the previous, the total number of patients that
were cured after only 3 days of treatment using MTD-SLNs
emulgel was significantly higher than those using the market
product, which showed that a shorter period of treatment
was required.
In our study, vaginal MTD-SLNs emulgel was observed to
be faster and more effective in treatment than vaginal
Metron gel in the BV cases. The majority of the cases that
were treated by vaginal emulgel seemed to be pleased with
its quick cure (after 3 days of application) and a major
decrease in the recurrence rate compared to the generally
used commercial vaginal gel. Moreover, there was no irritation or significant adverse effects with the vaginal MTDSLNs emulgel.
Generally, treatment against BV emerged with MTD as the
drug of choice for its action against several anaerobic organisms. But, regrettably, the cure rates associated with MTD
ranged from 50–80%, with a high recurrence rate (Schwebke
& Desmond, 2011). One of the main reasons for treatment
failure is vaginal biofilm which plays a key role not only in
BV pathogenesis but also in its recurrence (Tomas et al.,
2020). Bacterial biofilms are established when an accumulation of adherent microorganisms occurs on a living surface
(Malaekeh-Nikouei et al., 2020). The biofilm’s structure avoids
the antimicrobial penetration in the matrix as well as the direct contact with the microorganisms. Concurrently, an
increase in antibiotics resistance is detected, which leads to
treatment failures (Tomas et al., 2020). Several studies

recommend the lack of effectiveness of conventional antimicrobial treatments and high recurrence rates of BV
because of their failure to destroy the vaginal biofilm in addition to their adverse effects on healthy vaginal microflora
(Tomas et al., 2020).
The antimicrobial agents’ encapsulation into lipid-based
carriers has many advantages such as deactivation resistance,
as well as reduction of adverse effects and systematic toxicity. Furthermore, the prolonged-release behavior of antibiotics from the lipid nanoformulations was reported in biofilm
eradication and improved antibacterial activities (MalaekehNikouei et al., 2020). According to several studies, SLNs were
found to have potential antibiofilm activity against many
types of bacteria (Singh et al., 2014; Islan et al., 2016; Sharma
et al., 2016; Akhtari et al., 2020). SLNs serve as a coating
agent for the antibacterial drug thus do not allow the bacterial adhesion to the surface of the formulation and therefore
preventing bacterial biofilm formation (Taylor et al., 2014).
Simultaneously, the nano size of SLNs enables the drug
penetration inside the cells and hence destroys the organism
successfully (Singh et al., 2014).
Accordingly, these results highlight the effectiveness of
the therapeutic value of the optimized MTD-SLNs emulgel
formulation over the commercial formulation.

Conclusion
BV is one of the major vaginal infections in women of reproductive age but the traditional treatment has a high most
recurrence rate. So, in this study, we successfully developed
vaginal emulgel of MTD loaded in SLNs optimized formula.
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Clinically, MTD-SLNs vaginal emulgel had a significant therapeutic effect against BV symptoms according to Amsel’s criteria in comparison to the commercial product as well as
low recurrent rate. Therefore, the abovementioned results
proved that the optimized formulation could be a potential
delivery system for vaginal application of MTD.
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